Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 4, 2025

Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 3, 2025

2 Under-the-Radar Stocks to Buy Heading Into 2026

Axsome Therapeutics boasts a deep late-stage pipeline with billions in potential revenue opportunity. Exelixis' core franchise remains strong while it develops promising new medicines.

The Motley Fool • Dec 2, 2025

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in December:

GlobeNewsWire • Nov 20, 2025

2 Monster Stocks in the Making

Viking Therapeutics is developing innovative medicines in a fast-growing area. Axsome Therapeutics is generating strong sales, and solid regulatory progress could improve things.

The Motley Fool • Nov 10, 2025

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator

GlobeNewsWire • Nov 6, 2025

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic Bio, Inc. (“Baergic”), today announced that Avenue has entered into an agreement for Baergic to be acquired by Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome”), including the global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 subtype-selective receptor positive allosteric modulator (PAM). BAER-101 was originally licensed by Baergic from AstraZeneca AB (“AstraZeneca”) and will be referred to as AXS-17 by Axsome going forward.

GlobeNewsWire • Nov 6, 2025

Axsome Therapeutics Stock In A Buy Zone. Analysts See Profit On The Horizon.

Axsome Therapeutics stock is in a buy zone and is up about 58% this year. The company's biggest revenue generator is a depression treatment.

Investors Business Daily • Nov 5, 2025

Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer

Axsome Therapeutics remains a 'Sell' due to an undifferentiated CNS pipeline, heavy SG&A, and ongoing net losses despite revenue growth. Auvelity's sales growth appears largely marketing-driven and competes in a crowded, generic-heavy depression market. AXS-05 for Alzheimer's agitation offers some promise as a non-antipsychotic, but real-world adoption and blockbuster potential are limited.

Seeking Alpha • Nov 5, 2025

AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.

Zacks Investment Research • Nov 4, 2025